Lexicon Pharmaceuticals And Ipsen Biopharmaceuticals Announce Health Canada Approval Af XERMELO For Treatment Of Refractory Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
Benzinga_Newsdesk